The primary reference document for safety pharmacology is ICH S7A, followed by many key regulatory documents which either focus on or mention safety pharmacology: 
* ICH S7A: Safety pharmacology studies for human pharmaceuticals. [http://www.ich.org/fileadmin/Public_Web_Site/ICH_Products/Guidelines/Safety/S7A/Step4/S7A_Guideline.pdf]. 
* ICH S7B: Nonclinical evaluation of the potential for delayed ventricular repolarization (QT interval prolongation) by human pharmaceuticals. [http://www.ich.org/fileadmin/Public_Web_Site/ICH_Products/Guidelines/Safety/S7B/Step4/S7B_Guideline.pdf].
* ICH S6(R1): Preclinical safety evaluation of  biotechnology-derived pharmaceuticals. [http://www.ich.org/fileadmin/Public_Web_Site/ICH_Products/Guidelines/Safety/S6_R1/Step4/S6_R1_Guideline.pdf].
* ICH S9: Nonclinical evaluation for anticancer pharmaceuticals. [http://www.ich.org/fileadmin/Public_Web_Site/ICH_Products/Guidelines/Safety/S9/Step4/S9_Step4_Guideline.pdf].
* ICH M3(R2): Guidance on nonclinical safety studies for the conduct of human clinical trials and marketing authorisation for pharmaceuticals. [http://www.ich.org/fileadmin/Public_Web_Site/ICH_Products/Guidelines/Multidisciplinary/M3_R2/Step4/M3_R2__Guideline.pdf].
* ICH E14: Clinical evaluation of QT/QTc interval and proarrhythmic potential for non-antiarrhythmic drugs. [http://www.ich.org/fileadmin/Public_Web_Site/ICH_Products/Guidelines/Efficacy/E14/E14_Guideline.pdf].
* EMEA/CHMP/SWP/94227/2004. Adopted by CHMP. Guideline on the Non-Clinical Investigation of the Dependence Potential of Medicinal Products. [http://cpdd.org/Pages/Index/Index_PDFs/EMEAGuidelinesOnTheNonClinicalInvestigationOfTheDependencePotentialOfMedicinalProducts.pdf].
* FDA U.S. Department of Health and Human Services Food and Drug Administration - Center for Drug Evaluation and Research (CDER). Guidance for Industry. Assessment of abuse potential of drugs. Final Guidance. [https://www.fda.gov/downloads/drugs/guidances/ucm198650.pdf].
* FDA U.S. Department of Health and Human Services Food and Drug Administration - Center for Drug Evaluation and Research (CDER). Guidance for Industry. Exploratory IND studies. [https://www.fda.gov/downloads/drugs/guidancecomplianceregulatoryinformation/guidances/ucm078933.pdf].